

AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in the application.

1. (Currently Amended) Tetrapeptide ~~lysyl-glutamyl-aspartyl-tryptophane amide of the general formula~~ Lys-Glu-Asp-Trp-NH₂[SEQ ID NO:1].
2. (Canceled).
3. (Previously Presented) A pharmaceutical composition comprising a pharmaceutically admissible carrier and tetrapeptide Lys-Glu-Asp-Trp-NH₂[SEQ ID NO:1].
4. (Previously Presented) The pharmaceutical composition of claim 3, which is suitable for oral administration.
5. (Previously Presented) The pharmaceutical composition of claim 3, which is suitable for parenteral administration.
6. (Currently Amended) A method of ~~prophylaxis and/or~~ treatment of diabetes mellitus, which consists in administering to the patient an effective amount of tetrapeptide Lys-Glu-Asp-Trp-NH₂ [SEQ ID NO:1] at least once a day for a period necessary for attaining a therapeutic effect.
7. (Previously Presented) The method of claim 6 wherein the tetrapeptide is administered parenterally.
8. (Previously Presented) The method of claim 6 wherein the tetrapeptide is administered orally.
9. (Previously Presented) The method of claim 6 wherein the tetrapeptide is administered in doses of 0.1-30 mg/kg of the body weight.